Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11133362 | 1.00 | PRMT1 (0.59) | PRMT1ADRA1AALDH1A1POLBTAAR1 | |
| SCHEMBL11133946 | 1.00 | PRMT1 (0.59) | PRMT1ADRA1AALDH1A1POLBTAAR1 | |
| SCHEMBL11141321 | 1.00 | PRMT1 (0.59) | PRMT1ADRA1AALDH1A1POLBTAAR1 | |
| SCHEMBL81977 | 1.00 | PRMT1 (0.59) | PRMT1ADRA1AALDH1A1POLBTAAR1 | |
| SCHEMBL11137045 | 1.00 | PRMT1 (0.59) | PRMT1ADRA1AALDH1A1POLBTAAR1 | |
| SCHEMBL24686717 | 1.00 | PRMT1 (0.59) | PRMT1ADRA1AALDH1A1POLBTAAR1 | |
| SCHEMBL8779381 | 1.00 | PRMT1 (0.59) | PRMT1ADRA1AALDH1A1POLBTAAR1 | |
| SCHEMBL8779450 | 1.00 | PRMT1 (0.59) | PRMT1ADRA1AALDH1A1POLBTAAR1 | |
| SCHEMBL8779440 | 1.00 | PRMT1 (0.59) | PRMT1ADRA1AALDH1A1POLBTAAR1 | |
| SCHEMBL11136996 | 1.00 | PRMT1 (0.59) | PRMT1ADRA1AALDH1A1POLBTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128740-A1 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | ALFASIGMA S.P.A. (IT) | 2021-05-06 | — | — | US | disclosed |
| EP-3600444-A1 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | Alfasigma S.p.A. (IT) | 2020-02-05 | — | — | EP | disclosed |
| CN-110475572-A | Antibody drug conjugate (ADC) based on hdac inhibitor and the purposes in therapy | ALFASIGMA SPA | 2019-11-19 | — | — | CN | disclosed |
| WO-2018178060-A1 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | ALFASIGMA S.P.A. (IT) | 2018-10-04 | — | — | WO | disclosed |
| EP-3381474-A1 | HISTONE DEACETYLASE INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCS) AND USE IN THERAPY | Alfasigma S.p.A. (IT) | 2018-10-03 | — | — | EP | disclosed |
| EP-1534269-B1 | OXIME CONJUGATES AND METHODS FOR THEIR FORMATION AND USE | GEN HOSPITAL CORP (US) | 2013-10-30 | — | — | EP | disclosed |
| US-8361442-B2 | Oxime conjugates and methods for their formation and use | THE GENERAL HOSPITAL CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120027680-A1 | OXIME CONJUGATES AND METHODS FOR THEIR FORMATION AND USE | THE GENERAL HOSPITAL CORPORATION (US) | 2012-02-02 | — | — | US | disclosed |
| US-8030459-B2 | Oxime conjugates and methods for their formation and use | THE GENERAL HOSPITAL CORPORATION (US) | 2011-10-04 | — | — | US | disclosed |
| US-20060058513-A1 | Oxime conjugates and methods for their formation and use | ENERGY, UNITED STATES DEPARTMENT OF | 2006-03-16 | — | — | US | disclosed |
| EP-1534269-A1 | OXIME CONJUGATES AND METHODS FOR THEIR FORMATION AND USE | THE GENERAL HOSPITAL CORPORATION (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004009082-A1 | OXIME CONJUGATES AND METHODS FOR THEIR FORMATION AND USE | THE GENERAL HOSPITAL CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058513-A1 | Oxime conjugates and methods for their formation and use | GNE, OGA, SORD | PRMT1 2540/4885ADRA1A 2745/4885ALDH1A1 108/4885 |
| US-20210128740-A1 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | ERBB3, HDAC6, ERBB2 | PRMT1 1193/4885ADRA1A 3407/4885ALDH1A1 1532/4885 |
| US-20120027680-A1 | OXIME CONJUGATES AND METHODS FOR THEIR FORMATION AND USE | GNE, SORD, OGA | PRMT1 2573/4885ADRA1A 2705/4885ALDH1A1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.